Search results
Showing 766 to 780 of 2208 results for guidelines
The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)
NICE has developed a Medtech Innovation Briefing (MIB) on the PressureWire fractional flow reserve measurement system
Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.
Asthma. Patient decision aid on asthma inhalers and climate change (BTS, NICE, SIGN)
decision aid reflects the commitment of NICE, the Scottish Intercollegiate Guidelines Network (SIGN) and the British Thoracic Society...
Axonics sacral neuromodulation system for faecal incontinence (MIB259)
NICE has developed a medtech innovation briefing (MIB) on Axonics sacral neuromodulation system for faecal incontinence .
NICE no longer plans to develop guidance on Freelite assays for diagnosing multiple myeloma and related conditions in primary care.
Show all sections
Sections for HTG619
Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.
Capsule sponge tests for surveillance of Barrett's oesophagus (provisional title)
In development Reference number: GID-HTE10070 Expected publication date: TBC
This indicator covers the percentage of mothers who give their babies breast milk in the first 48 hours after delivery. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG33
We have a library of over 200 quality standards and a single menu of indicators, designed to help define and measure quality in health, public health and social care.
This indicator covers the the percentage of patients with a current diagnosis of heart failure with reduced ejection fraction, who are currently treated with an angiotensin-converting enzyme inhibitor or angiotensin receptor-neprilysin inhibitor or angiotensin II receptor blocker, a beta blocker, a mineralocorticoid receptor antagonist and a sodium glucose co-transporter-2 inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease.
The standing committees were responsible for the development of our public health guidance.
Evidence-based recommendations on everolimus (Afinitor) and sunitinib (Sutent) for treating neuroendocrine tumours in adults.